MicroRNA-197 Mediates the Overgrowth and Anti-Apoptotic Effects by Downregulating Insulin-Like Growth Factor-Binding Protein-3 During Nephroblastoma Tumorigenesis

References

• Oue T, Fukuzawa M, Koshinaga T, Okita H, Nozaki M, Chin M, et al. Management of pediatric renal tumor: Past and future trials of the Japan Wilms Tumor Study Group. Pediatr Int 2015;57(5):828–31.
   PubMed Web of Science ®Google Scholar
• Ha TC, Spreafico F, Graf N, Dallorso S, Dome JS, Malogolowkin M, et al. An international strategy to determine the role of high dose therapy in recurrent Wilms tumour. Eur J Cancer 2013;49(1):194–210.
   PubMed Web of Science ®Google Scholar
• Lee JS, Padilla B, DuBois SG, Oates A, Boscardin J, Goldsby RE. Second malignant neoplasms among children, adolescents and young adults with Wilms tumor. Pediatr Blood Cancer 2015;62(7):1259–1264.
   PubMed Web of Science ®Google Scholar
• Cabezali Barbancho D, Guerrero Ramos F, Lopez Vazquez F, Aransay Bramtot A, Gomez Fraile A. Laparoscopic approach for Wilms tumor. Surg Laparosc Endosc Percutan Tech 2014;24(1):22–25.
   PubMed Web of Science ®Google Scholar
• Kieran K, Ehrlich PF. Current surgical standards of care in Wilms tumor. Urol Oncol 2016;34(1):13–23.
   PubMed Web of Science ®Google Scholar
• Sarin YK, Raj P. Recurrent monophasic Wilms tumor in pelvic kidney—A therapeutic challenge. APSP J Case Rep 2015;6(3):25.
   PubMedGoogle Scholar
• Lee SY, Kim KR, Park JY, Ro JY. Wilms tumor with long-delayed recurrence: 25 sources after initial treatment. Korean J Urol 2012;53(4):288–292.
   PubMedGoogle Scholar
• Tian F, Yourek G, Shi X, Yang Y. The development of Wilms tumor: from WT1 and microRNA to animal models. Biochim Biophys Acta 2014;1846(1):180–187.
   PubMed Web of Science ®Google Scholar
• Kim KM, Lim SK. Role of miRNAs in bone and their potential as therapeutic targets. Curr Opin Pharmacol 2014;16:133–141.
   PubMed Web of Science ®Google Scholar
• Shaker O, Maher M, Nassar Y, Morcos G, Gad Z. Role of microRNAs-29b-2,-155,-197 and-205 as diagnostic biomarkers in serum of breast cancer females. Gene 2015;560(1):77–82.
   PubMed Web of Science ®Google Scholar
• Abdellatif M. Differential expression of microRNAs in different disease states. Circ Res 2012;110(4):638–650.
   PubMed Web of Science ®Google Scholar
• Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101(9):2999–3004.
   PubMed Web of Science ®Google Scholar
• Lehmann U, Streichert T, Otto B, Albat C, Hasemeier B, Christgen H, et al. Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer 2010;10:109.
   PubMed Web of Science ®Google Scholar
• Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA. MicroRNA expression variability in human cervical tissues. PloS one 2010;5(7):e11780.
   Google Scholar
• Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 2009;7(8):1234–1243.
   PubMed Web of Science ®Google Scholar
• Dai W, Wang C, Wang F, Wang Y, Shen M, Chen K, et al. Anti-miR-197 inhibits migration in HCC cells by targeting KAI 1/CD82. Biochem. Biophys Res Commun 2014;446(2):541–548.
   PubMed Web of Science ®Google Scholar
• Abd-El-Fattah AA, Sadik NA, Shaker OG, Aboulftouh ML. Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem Biophys 2013;67(3):875–884.
   PubMed Web of Science ®Google Scholar
• Mavridis K, Gueugnon F, Petit-Courty A, Courty Y, Barascu A, Guyetant S, et al. The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients. Br J Cancer 2015;112(9):1527–1535.
   PubMed Web of Science ®Google Scholar
• Hamada S, Satoh K, Miura S, Hirota M, Kanno A, Masamune A, et al. miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physio 2013;228(6):1255–1263.
   PubMed Web of Science ®Google Scholar
• Zou D, Wang D, Li R, Tang Y, Yuan L, Long X, et al. MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK. Tumour Biol 2015;36(9):6725–6732.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li F, Saha MN, Abdi J, Qiu L, Chang H. miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma. Clin Cancer Res 2015;21(10):2399–2411.
   PubMed Web of Science ®Google Scholar
• Xin J, Zhang XK, Xin DY, Li XF, Sun DK, Ma YY, et al. FUS1 acts as a tumor-suppressor gene by upregulating miR-197 in human glioblastoma. Oncol Rep 2015;34(2):868–876.
   PubMed Web of Science ®Google Scholar
• Wu X, Ling J, Fu Z, Ji C, Wu J, Xu Q. Effects of miRNA-197 overexpression on proliferation, apoptosis and migration in levonorgestrel treated uterine leiomyoma cells. Biomed Pharmacother 2015;71:1–6.
   PubMed Web of Science ®Google Scholar
• Xiong HL, Zhou SW, Sun AH, He Y, Li J, Yuan X. MicroRNA197 reverses the drug resistance of fluorouracilinduced SGC7901 cells by targeting mitogenactivated protein kinase 1. Mol Med Rep 2015;12(4):5019–5025.
   PubMed Web of Science ®Google Scholar
• Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as Potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008;14(9):2588–2592.
   PubMed Web of Science ®Google Scholar
• Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M, et al. Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ 2014;21(5):774–782.
   PubMed Web of Science ®Google Scholar
• Li L, Huang X, Huo K. IGFBP3 polymorphisms and risk of cancer: a meta-analysis. Mol Biol Rep 2010;37(1):127–140.
   PubMed Web of Science ®Google Scholar
• Liu C, Tang W, Chen S, Wang Y, Qiu H, Yin J, et al. IGFBP3 polymorphisms and risk of esophageal cancer in a Chinese population. Int J Clin Exp Med 2015;8(9):17006–17014.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhu Y, Liu F, Gu C, Chen H, Xu J, et al. Genetic variants in insulin-like growth factor binding protein-3 are associated with prostate cancer susceptibility in Eastern Chinese Han men. Onco Targets 2016;9:61–66.
   Google Scholar
• Johnson MA, Firth SM. IGFBP-3: a cell fate pivot in cancer and disease. Growth Horm IGF Res 2014;24(5):164–173.
   PubMed Web of Science ®Google Scholar
• Baxter RC. Nuclear actions of insulin-like growth factor binding protein-3. Gene 2015;569(1):7–13.
   PubMed Web of Science ®Google Scholar
• Marzec KA, Baxter RC, Martin JL. Targeting insulin-like growth factor binding protein-3 signaling in triple-negative breast cancer. BioMed Res Int 2015;2015:638526.
   PubMedGoogle Scholar
• Liu L, Liao ZL, Yan XJ, Liu J, Wang XO, Fan H. [Expression of insulin-like growth factor binding protein 3 in acute myeloid leukemia and its clinical significance]. Zhongguo shi yan xue ye xue za zhi/ J Exp Hematol 2015;23(4):935–939.
   Google Scholar
• Perez-Carbonell L, Balaguer F, Toiyama Y, Egoavil C, Rojas E, Guarinos C, et al. IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer. PloS one 2014;9(8):e104285.
   Google Scholar
• Duggan C, Wang CY, Neuhouser ML, Xiao L, Smith AW, Reding KW, et al. Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer. Int J Cancer 2013;132(5):1191–1200.
   PubMed Web of Science ®Google Scholar
• Du Y, Long Q, Shi Y, Liu X, Li X, Zeng J, et al. Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer. Oncol Rep 2015;34(5):2273–2281.
   PubMed Web of Science ®Google Scholar
• Han J, Jogie-Brahim S, Harada A, Oh Y. Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-kappaB signaling. Cancer Lett 2011;307(2):200–210.
   PubMed Web of Science ®Google Scholar
• Panasiti V, Naspi A, Devirgiliis V, Curzio M, Roberti V, Curzio G, et al. Correlation between insulin-like growth factor binding protein-3 serum level and melanoma progression. J Am Acad Dermatol 2011;64(5):865–872.
   PubMed Web of Science ®Google Scholar
• Huang YF, Cheng WF, Wu YP, Cheng YM, Hsu KF, Chou CY. Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocr Relat Cancer 2014;21(2):217–229.
   PubMed Web of Science ®Google Scholar
• Hirakawa T, Yashiro M, Murata A, Hirata K, Kimura K, Amano R, et al. IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer. BMC Cancer 2013;13:392.
   PubMed Web of Science ®Google Scholar
• Sun JM, Jun HJ, Ko YH, Park YH, Ahn YC, Son YI, et al. Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck. Oral Oncol 2011;47(8):714–719.
   PubMed Web of Science ®Google Scholar
• Han JJ, Xue DW, Han QR, Liang XH, Xie L, Li S, et al. Induction of apoptosis by IGFBP3 overexpression in hepatocellular carcinoma cells. Asian Pac J Cancer Prev 2014;15(23):10085–10089.
   PubMedGoogle Scholar
• Yin J, Ding J, Huang L, Tian X, Shi X, Zhi L, et al. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression. Anat Rec (Hoboken) 2013;296(10):1568–1575.
   PubMedGoogle Scholar
• Ling J, Jiang L, Zhang C, Dai J, Wu Q, Tan J. Upregulation of miR-197 inhibits cell proliferation by directly targeting IGFBP5 in human uterine leiomyoma cells. In Vitro Cell Dev Biol-Anim 2015;51(8):835–842.
   PubMed Web of Science ®Google Scholar
• Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008;9(2):102–114.
   PubMed Web of Science ®Google Scholar
• Meister G. miRNAs get an early start on translational silencing. Cell 2007;131(1):25–28.
   PubMed Web of Science ®Google Scholar
• Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 2005;122(4):553–563.
   PubMed Web of Science ®Google Scholar
• Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433(7027):769–773.
   PubMed Web of Science ®Google Scholar